Philips Wins FDA Nod for AI-Powered, Detector-Based Spectral CT

Philips has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Spectral CT Verida system, a next-gen, artificial intelligence (AI)-powered spectral computed tomography (CT) system.

Verida features Spectral Precise Image with a third-generation Nano-panel Precise dual-layer detector with intrinsic noise reduction. It also include an AI-based deep learning reconstruction engine, which was designed to reduce noise and enhance image quality. Clinicians can customize optimal image de-noising according to preference.

The spectral CT allows always-on spectral imaging without needing separate scans or workflow changes. Its system and software enhancements include improvements to the spectral result generation pipeline and updated computing infrastructure to support performance and usability, Philips said.

Verida reconstructs 145 images per second so entire exams automatically appear in under 30 seconds. This is two times faster than previously, allowing up to 270 exams per day.

Clinicians can access conventional and spectral results at the same time by capturing both high- and low-energy data in a single acquisition, supporting enhanced tissue characterization and material differentiation. The method removes the need for pre-selection or repeat scans.

Verida is intended for diagnostic imaging in radiology, interventional radiology, and cardiology, and in oncology as part of treatment preparation and radiation therapy planning. It’s indicated for head, whole body, cardiac, and vascular CT applications in patients of all ages. The system is also meant for low-dose CT lung cancer screening when done within established screening protocols.

“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets,” said Dan Xu, Business Leader of CT at Philips. “By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”